# Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia

> **NCT03066739** · PHASE2 · TERMINATED · sponsor: **University of California, Irvine** · enrollment: 8 (actual)

## Conditions studied

- Hyperalgesia

## Interventions

- **DRUG:** Remifentanil
- **DRUG:** Remifentanil+ Placebo
- **DRUG:** Remifentanil +ultra-low dose naloxone

## Key facts

- **NCT ID:** NCT03066739
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-25
- **Primary completion:** 2024-12-10
- **Final completion:** 2024-12-10
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Study terminated early due to low enrollment. Only 8 participants enrolled out of the target 105.
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03066739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03066739, "Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT03066739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*